Foghorn Therapeutics Return on Equity

Foghorn Therapeutics (FHTX) currently reports a ROE of 79.69%. That is above the Healthcare sector average of 20.86%. Use the charts on this page to explore Foghorn Therapeutics's ROE history and peer comparisons.

Foghorn Therapeutics's ROE of 79.69% is higher than the Healthcare sector average of 20.86%. That is roughly 282.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Foghorn Therapeutics's current 79.69% should be judged against Healthcare norms (sector average: 20.86%) and against FHTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 79.69%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Foghorn Therapeutics, and consider following FHTX for alerts when major investors trade the stock.

Foghorn Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 79.69% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FHTX with unrelated industries.